{'fraction_non_alphanumeric': 0.023809523809523808, 'fraction_numerical': 0.0, 'mean_word_length': 6.008333333333334, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Vasculitis in the seriously ill patient: diagnostic approaches and therapeutic options in ANCA-associated vasculitis.

The clinical severity of ANCA-associated vasculitides (AAV) ranges widely from relatively benign courses to rapidly progressive, acutely life-threatening disease. The aggressiveness in the individual patient depends on the site and size of vessels involved and on the severity of the associated inflammatory/immunological features. The scope of life-threatening lesions reaches from the well-known pulmonary renal syndrome to cardiac, gastrointestinal and central nervous system manifestations. Treatment must be instituted as soon as possible and consists of daily cyclophosphamide and high-dose glucocorticosteroids. Plasmapheresis, intravenous immunoglobulin, and monoclonal antibodies may be of benefit in some cases.